synagis
(palivizumab)Swedish Orphan Biovitrum AB (publ)
Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients: 1) born prematurely (≤35 weeks) and ≤6 months at RSV season start; 2) with BPD requiring treatment and ≤24 months; 3) with significant CHD and ≤24 months at RSV season start.